

TECEIVED

DEC 3 1 2002

PATENT

JE MAR 2 6 7003 TOO IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

William P. Van Antwerp et al.

Examiner:

Unassigned

Serial No .:

10/035,831

Group Art Unit:

1762

Filed:

12/28/2001

Docket No .:

047711-0273

Title:

STABILIZING CATHETER FOR PROTEIN DRUG DELIVERY

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described herein, are being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on December 16, 2002.

Juanita Soberanis

INFORMATION DISCLOSURE STATEMENT

RECEIVED

Commissioner for Patents Washington, D.C. 20231

JAN 1 6 2003

Dear Sir:

TECH CENTER 1600/2900

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the issuance of a first Office Action in the above-identified application. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge fees, if any, to Deposit Account No. 50-0872.

Respectfully submitted,

By / A

Reg. No.: 32,933

FOLEY & LARDNER 2029 Century Park East Suite 3500

Los Angeles, CA 90067-3021

Tel.: (310) 277-2223 Fax: (310) 557-8475

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE			ATTY. DOCKET NO.		SERIAL NO.		
(MODIFIED)		PATENT AND TRADEMARK OFFICE			047711-0273		10/035,831		
SUPPLEMENTAL					APPLICANT				
O I P INFO	RMAT	ON DISCLOSURE	CITATION	William P. Van Antwerp et al.					
					FILING DATE		GROUP ART UNIT		
ncr 2 6 2007	2 (Wises	everal sheets if necessary)			12/28/2001		1762		
DEG 2 3 3	<u> </u>			TEN	IT DOCUMENTS				
<u> </u>	9 0.5.17				., 5000		FILING	DATE	
EXAMPLEA	REF	DOCUMENT	DATE		NAME	CLASS	SUB- CLASS	IF ·	
		NUMBER						APPRO	PRIATE
	A1	5,702,372	12/30/1997	Nel	son	604	264	02/08/1995 MAR 2 6 700	
	А								A
	Α					REC	-	Na	TEO
	Α					110	CIVER	3 ~ ~ ?	2 ,
	A		-			DEC 3	1 2002	POI ,	700
	A					TO			7>
						101	100		-00
	A							1	
	A								
	Α						1		
			FOREIGN	PA	TENT DOCUMENTS				
	REF	DOCUMENT	DATE	COUNTRY		CLASS	SUB- CLASS		LATION
		NUMBER					OLAGO	YES	NO
	В					`		 	
	В								
	В							<u> </u>	
	В								
					Author, Title, Date, P				
	C1	Program for Plasn Surface Modificati	na Polymerization on: Relevance to	Dep Adh	osition Symposium, <u>Se</u> <u>esion,</u> Pages 1-12.	cond Internation	nal Symposiu	m on Polyr	<u>mer</u>
	C2	Brian Rudie, Osmonics, <u>Hydrophilicity and Hydrophobicity</u> , Pages 1-9. Richard H. Griffey et al., Biophysical Journal/Biophysical Society, <u>Characterization of the Carbamino Adducts of Insulin</u> , Vol. 54, August 1988, Pages 295-300.							
	СЗ								
	C4	Ewa Ciszak et al., Current Biology Ltd ISSN 0969-2126, Role of C-Terminal B-Chain Residues in Insulin Assembly: The Structure of Hexameric Lys B28 Pro B29 human insulin, June 1995, Vol. 3 No. 6, Pages 615-62							
			<u> </u>				- "		
EXAMINER				DATE CONSIDERED					
* EXA	MINER throug	 Initial if citation h citation if not it 	n considered, v n conformance	whet e an	her or not citation i d not considered.	s in conform Include any d	ance with footbody	iner 609 form wi	e; טרמw ith next

communication to applicant.